These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 39072983)
1. The liquid-liquid phase separation signature predicts the prognosis and immunotherapy response in hepatocellular carcinoma. Wang Z; Wang G; Zhao P; Sun P J Cell Mol Med; 2024 Jul; 28(14):e18446. PubMed ID: 39072983 [TBL] [Abstract][Full Text] [Related]
2. Predictive value of a stemness-based classifier for prognosis and immunotherapy response of hepatocellular carcinoma based on bioinformatics and machine-learning strategies. Chen E; Zou Z; Wang R; Liu J; Peng Z; Gan Z; Lin Z; Liu J Front Immunol; 2024; 15():1244392. PubMed ID: 38694506 [TBL] [Abstract][Full Text] [Related]
3. Identification of PANoptosis-related subtypes, construction of a prognosis signature, and tumor microenvironment landscape of hepatocellular carcinoma using bioinformatic analysis and experimental verification. Ouyang G; Li Q; Wei Y; Dai W; Deng H; Liu Y; Li J; Li M; Luo S; Li S; Liang Y; Pan G; Yang J; Gan T Front Immunol; 2024; 15():1323199. PubMed ID: 38742112 [TBL] [Abstract][Full Text] [Related]
4. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma. Wang S; Bai H; Fei S; Miao B Biochem Genet; 2024 Jun; 62(3):2332-2351. PubMed ID: 37898914 [TBL] [Abstract][Full Text] [Related]
5. Metastasis and basement membrane-related signature enhances hepatocellular carcinoma prognosis and diagnosis by integrating single-cell RNA sequencing analysis and immune microenvironment assessment. Wei S; Tan J; Huang X; Zhuang K; Qiu W; Chen M; Ye X; Wu M J Transl Med; 2024 Jul; 22(1):711. PubMed ID: 39085893 [TBL] [Abstract][Full Text] [Related]
6. Immune- and metabolism-related gene signature analysis uncovers the prognostic and immune microenvironments of hepatocellular carcinoma. Gu Y; Ma E; Jiang S; Shan Z; Xia G; Ma R; Fu J; Wang Z J Cancer Res Clin Oncol; 2024 Jun; 150(6):311. PubMed ID: 38896142 [TBL] [Abstract][Full Text] [Related]
7. High ratio of resident to exhausted CD4 + T cells predicts favorable prognosis and potentially better immunotherapeutic efficacy in hepatocellular carcinoma. Zuo A; Lv J; Jia W; Ba Y; Liu S; Zhang Y; Weng S; Xu H; Liu L; Wang L; Han X; Liu Z BMC Cancer; 2024 Sep; 24(1):1152. PubMed ID: 39289669 [TBL] [Abstract][Full Text] [Related]
8. Constructing and validating pan-apoptosis-related features for predicting prognosis and immunotherapy response in hepatocellular carcinoma. He Y; Wu S; Chen L; Chen W; Zhan X; Li J; Wang B; Gao C; Wu J; Wang Q; Li M; Liu B Biochem Biophys Res Commun; 2024 Nov; 734():150633. PubMed ID: 39243678 [TBL] [Abstract][Full Text] [Related]
9. A novel super-enhancer-related risk model for predicting prognosis and guiding personalized treatment in hepatocellular carcinoma. Wu Q; Li P; Tao X; Lin N; Mao B; Xie X BMC Cancer; 2024 Sep; 24(1):1087. PubMed ID: 39223584 [TBL] [Abstract][Full Text] [Related]
10. An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma. Dai Y; Qiang W; Lin K; Gui Y; Lan X; Wang D Cancer Immunol Immunother; 2021 Apr; 70(4):967-979. PubMed ID: 33089373 [TBL] [Abstract][Full Text] [Related]
11. Lysosome-Related Genes and RNF19B as Prognostic Markers for Survival and Immunotherapy Efficacy in Hepatocellular Carcinoma. Li J; Wang H; Lu Q; Han J; Xu H; Sun P; Xu Q; Huang J; Ji J Clin Transl Gastroenterol; 2024 Jun; 15(6):e1. PubMed ID: 38546132 [TBL] [Abstract][Full Text] [Related]
12. A signature of 33 immune-related gene pairs predicts clinical outcome in hepatocellular carcinoma. Sun XY; Yu SZ; Zhang HP; Li J; Guo WZ; Zhang SJ Cancer Med; 2020 Apr; 9(8):2868-2878. PubMed ID: 32068352 [TBL] [Abstract][Full Text] [Related]
13. Mitotic catastrophe heterogeneity: implications for prognosis and immunotherapy in hepatocellular carcinoma. Mao Z; Gao Z; Long R; Guo H; Chen L; Huan S; Yin G Front Immunol; 2024; 15():1409448. PubMed ID: 39015573 [TBL] [Abstract][Full Text] [Related]
14. Distinct cuproptosis patterns in hepatocellular carcinoma patients correlate with unique immune microenvironment characteristics and cell-cell communication, contributing to varied overall survival outcomes. Wang Y; Mang X; Guo X; Pu J Front Immunol; 2024; 15():1379690. PubMed ID: 38868777 [TBL] [Abstract][Full Text] [Related]
15. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment. Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776 [TBL] [Abstract][Full Text] [Related]
16. A novel prognostic model for predicting patient survival and immunotherapy responsiveness in hepatocellular carcinoma: insights into the involvement of T-cell proliferation. Tang S; Sun R; Tang K; Wei X; Liu M; Zhang H Clin Transl Oncol; 2024 Jun; 26(6):1368-1383. PubMed ID: 38123874 [TBL] [Abstract][Full Text] [Related]
17. Prognostic implication and immunotherapy response prediction of a novel ubiquitination-related gene signature in liver cancer. Pan RG; Zhou J; Wang XW; Cen XK; Zhou YP; Guo YY; Feng XF Aging (Albany NY); 2024 Jun; 16(11):10142-10164. PubMed ID: 38870259 [TBL] [Abstract][Full Text] [Related]
18. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma. Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X Front Immunol; 2023; 14():1218661. PubMed ID: 37662906 [TBL] [Abstract][Full Text] [Related]
19. Histamine-related genes participate in the establishment of an immunosuppressive microenvironment and impact the immunotherapy response in hepatocellular carcinoma. Zhang X; Zheng P; Meng B; Zhuang H; Lu B; Yao J; Han F; Luo S Clin Exp Med; 2024 Jun; 24(1):129. PubMed ID: 38884870 [TBL] [Abstract][Full Text] [Related]
20. Developing a prognostic model for hepatocellular carcinoma based on MED19 and clinical stage and determining MED19 as a therapeutic target. Jin X; Zhang Y; Hu W; Liu C; Cai D; Sun J; Wei Q; Cai Q J Cancer Res Clin Oncol; 2024 Oct; 150(10):446. PubMed ID: 39369139 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]